The FDA approved a pre-surgery bladder cancer combo
The FDA approved durvalumab, sold as Imfinzi, plus enfortumab vedotin before bladder removal, then durvalumab afterward, for muscle-invasive bladder cancer in patients who cannot take cisplatin or who decline it. In the 695-patient VOLGA trial the combo cut the risk of an event by about half. It is not a cure.

Read the original
The reporting lives at U.S. Food and Drug Administration. Our summary is checked against it, and we link it on every story.
The Food and Drug Administration on Nov. 13 approved durvalumab, sold as Imfinzi, given with enfortumab vedotin before the bladder is removed, followed by durvalumab afterward. The approval is for muscle-invasive bladder cancer in adults who cannot take cisplatin or who decline it. In the 695-patient VOLGA trial, the combination cut the risk of an event by about half, an event-free survival hazard ratio of 0.51, and improved overall survival, a hazard ratio of 0.58, compared with surgery alone. The agency approved the use six weeks early. Those ratios describe this trial, not every person with bladder cancer. The trial results were reported earlier from UCLA. This step is the approval that makes the regimen an FDA-cleared option. It is not a cure.
Health & Tech in MarylandSilver Spring, MarylandMedical researchCancer supportPublic healthGood news on November 13
More good news
Other stories in the same neighborhood of kindness.
Health & TechThe FDA approved Lembaz, the first drug shown to help infantile-onset Niemann-Pick C patients live longer
The FDA approved Lembaz, a spinal injection every two weeks. Among 36 treated patients, median survival was 8.5 years versus 4.9 in matched controls. It carries a boxed warning for hearing loss.
Verified · U.S. Food and Drug Administration
Health & TechFDA approves Roche's oral pill giredestrant for advanced breast cancer
The FDA approved giredestrant with everolimus for a specific advanced breast cancer. In a 207-patient trial it cut the risk of progression or death by 62%.
Verified · Reuters
Health & TechThe FDA approved the first drug for a rare kidney disease
The FDA approved Gazyva, obinutuzumab, for adults with primary membranous nephropathy at risk of getting worse, to induce remission of protein in the urine. In a 142-person trial, 36 percent reached complete remission at week 104, compared with 6 percent on tacrolimus. It is not a cure.
Verified · U.S. Food and Drug Administration